These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
294 related articles for article (PubMed ID: 32973534)
1. Research Progress of Genetic Structure, Pathogenic Mechanism, Clinical Characteristics, and Potential Treatments of Coronavirus Disease 2019. Zhu C; Sun B; Zhang X; Zhang B Front Pharmacol; 2020; 11():1327. PubMed ID: 32973534 [TBL] [Abstract][Full Text] [Related]
2. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). Bourgonje AR; Abdulle AE; Timens W; Hillebrands JL; Navis GJ; Gordijn SJ; Bolling MC; Dijkstra G; Voors AA; Osterhaus AD; van der Voort PH; Mulder DJ; van Goor H J Pathol; 2020 Jul; 251(3):228-248. PubMed ID: 32418199 [TBL] [Abstract][Full Text] [Related]
3. Relationship Between Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and the Etiology of Acute Kidney Injury (AKI). Chong WH; Saha BK Am J Med Sci; 2021 Mar; 361(3):287-296. PubMed ID: 33358501 [TBL] [Abstract][Full Text] [Related]
4. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Guo YR; Cao QD; Hong ZS; Tan YY; Chen SD; Jin HJ; Tan KS; Wang DY; Yan Y Mil Med Res; 2020 Mar; 7(1):11. PubMed ID: 32169119 [TBL] [Abstract][Full Text] [Related]
5. The Mechanisms and Animal Models of SARS-CoV-2 Infection. Jia W; Wang J; Sun B; Zhou J; Shi Y; Zhou Z Front Cell Dev Biol; 2021; 9():578825. PubMed ID: 33987176 [TBL] [Abstract][Full Text] [Related]
6. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19. Kuba K; Yamaguchi T; Penninger JM Front Immunol; 2021; 12():732690. PubMed ID: 35003058 [TBL] [Abstract][Full Text] [Related]
7. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. Cheng H; Wang Y; Wang GQ J Med Virol; 2020 Jul; 92(7):726-730. PubMed ID: 32221983 [TBL] [Abstract][Full Text] [Related]
8. Severe COVID-19: A Review of Recent Progress With a Look Toward the Future. Xie P; Ma W; Tang H; Liu D Front Public Health; 2020; 8():189. PubMed ID: 32574292 [TBL] [Abstract][Full Text] [Related]
9. Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective. Alnefaie A; Albogami S Saudi Pharm J; 2020 Nov; 28(11):1333-1352. PubMed ID: 32905015 [TBL] [Abstract][Full Text] [Related]
10. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection. Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH Front Immunol; 2020; 11():1022. PubMed ID: 32574260 [TBL] [Abstract][Full Text] [Related]
11. Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents. Khadke S; Ahmed N; Ahmed N; Ratts R; Raju S; Gallogly M; de Lima M; Sohail MR Virol J; 2020 Oct; 17(1):154. PubMed ID: 33059711 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme 2 in severe acute respiratory syndrome coronavirus and SARS-CoV-2: A double-edged sword? Yan T; Xiao R; Lin G FASEB J; 2020 May; 34(5):6017-6026. PubMed ID: 32306452 [TBL] [Abstract][Full Text] [Related]
13. COVID-19, Renin-Angiotensin System and Endothelial Dysfunction. Amraei R; Rahimi N Cells; 2020 Jul; 9(7):. PubMed ID: 32660065 [TBL] [Abstract][Full Text] [Related]
14. Combination of C21 and ARBs with rhACE2 as a therapeutic protocol: A new promising approach for treating ARDS in patients with coronavirus infection. Soheili M; Haji-Allahverdipoor K; Khadem-Erfan MB; Baban B; Nikkhoo B; Eliasi A; Nasseri S Med J Islam Repub Iran; 2020; 34():120. PubMed ID: 33316002 [No Abstract] [Full Text] [Related]
15. Inflammation Triggered by SARS-CoV-2 and ACE2 Augment Drives Multiple Organ Failure of Severe COVID-19: Molecular Mechanisms and Implications. Iwasaki M; Saito J; Zhao H; Sakamoto A; Hirota K; Ma D Inflammation; 2021 Feb; 44(1):13-34. PubMed ID: 33029758 [TBL] [Abstract][Full Text] [Related]
16. Update on Immunology of COVID-19 Disease and Potential Strategy for Controlling. Dezfuli NK; Adcock IM; Montazami N; Mortaz E; Velayati A Tanaffos; 2020 Dec; 19(4):274-290. PubMed ID: 33959165 [TBL] [Abstract][Full Text] [Related]
17. Characterization of the angiotensin-converting enzyme 2 (ACE2), the main receptor for the SARS-CoV-2 virus. Jami G; Ataee M; Esmaeili V; Chamani S; Rezaei A; Naghizadeh A Am J Clin Exp Immunol; 2023; 12(3):24-44. PubMed ID: 37457503 [TBL] [Abstract][Full Text] [Related]
18. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Gheblawi M; Wang K; Viveiros A; Nguyen Q; Zhong JC; Turner AJ; Raizada MK; Grant MB; Oudit GY Circ Res; 2020 May; 126(10):1456-1474. PubMed ID: 32264791 [TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 pandemic and research gaps: Understanding SARS-CoV-2 interaction with the ACE2 receptor and implications for therapy. Datta PK; Liu F; Fischer T; Rappaport J; Qin X Theranostics; 2020; 10(16):7448-7464. PubMed ID: 32642005 [TBL] [Abstract][Full Text] [Related]
20. COVID-19 Is a Multifaceted Challenging Pandemic Which Needs Urgent Public Health Interventions. Contini C; Caselli E; Martini F; Maritati M; Torreggiani E; Seraceni S; Vesce F; Perri P; Rizzo L; Tognon M Microorganisms; 2020 Aug; 8(8):. PubMed ID: 32806657 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]